Answers are grounded in this paper and cite their sources.
PURPOSE: Carbon ions have biophysical advantages over photons, including a finite range, increased relative biological effectiveness, and lowered oxygen dependence. Maximum treatment flexibility is attainable with rotational beam delivery. We report our clinical experience using the carbon-ion gantry at the Heidelberg Ion Beam Therapy Center with intensity-controlled raster scanning capability, focusing on treatment toxicity. METHODS AND MATERIALS: A total of 1622 patients treated using the carbon-ion gantry between 2012 and 2026 were evaluated. Data were analyzed using descriptive statistics. Toxicity analysis was conducted using Common Terminology Criteria of Adverse Events v5.0. RESULTS: The median age preradiation therapy was 59 years (range, 18-91). Most patients had locally advanced tumors (21.8% T4; 11.2% T3) without regional lymph node metastases (45.4% N0). The most common treatment indications were sacrococcygeal tumors (n = 331; 20.4%), followed by tumors of the paranasal sinuses (n = 166; 10.2%) and the spine (n = 121; 7.5%). A total of 486 patients (30.0%) received carbon-ion reirradiation, the most frequent carbon-ion gantry treatment indication viewed across all patients. The most common particle therapy beam-angle number was 2 (range, 1-7). The use of more than 2 beam angles was particularly frequent in tumors of the skull base (45.8%) and the thoracic region (40.0%). High-grade (III and IV) acute and late toxicity rates were 2.4% and 4.2% in primary treatment. Mean numbers of acute and late grade I and II toxicity events per patient were 2.2 (95% confidence interval, 2.0-2.4) and 2.0 (95% confidence interval, 1.7-2.4), respectively. CONCLUSIONS: Carbon-ion radiation therapy using a heavy-ion gantry resulted in favorable toxicity rates in specific indications. Further interdisciplinary research demonstrating the clinical benefit of carbon-ion radiation therapy is required. This study provides more evidence supporting particle therapy facilities and may serve as a foundation for prospective clinical trials.
No takes yet. Share an insight, caveat, or question.
Dvornikovich et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: